House passes Biden-backed orphan drug reform

The US House of Representatives has passed a bill to amend exclusivity laws for drugs on the US Food and Drug Administration’s orphan drugs list.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Warren: Biden must ‘break patent barriers’ to drive down drug costs

26 April 2022 Senator Elizabeth Warren has urged the US Department of Health and Human Services to “break patent barriers” in order to foster competition to lower prescription drug prices.

Generics

11th circ ‘eviscerated’ orphan drug rights, says petition

14 April 2022 New Jersey pharma company Jacobus Pharmaceutical has asked the US Supreme Court to review an 11th Circuit verdict that it claims “eviscerated” decades of precedent regarding Orphan Drug Act exclusivity.

Americas

Eleventh Circuit finds FDA fell foul of Orphan Drug Act

4 October 2021 The US Court of Appeals for the Eleventh Circuit has found that the US Food and Drug Administration violated the exclusivity of a patent covering a drug for a rare autoimmune disorder, by approving the same treatment specifically for children.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

House passes Biden-backed orphan drug reform

More on this story

Editor's picks

Editor's picks

More features